Overview

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
Phase:
PHASE2
Details
Lead Sponsor:
Metsera